Zyversa Therapeutics Inc (ZVSA) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Zyversa Therapeutics Inc   (ZVSA)

Zyversa Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Zyversa Therapeutics Inc in the first quarter 2026?
Due to the lack of equity, it was not possible to calculate Zyversa Therapeutics Inc 's return on equity (ROE) in its first quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change - - - -29.24 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -24 -25 -26 -8 -9
Return On Equity (TTM) - - -932.6 % -111.39 % -109.54 %
ZVSA's Total Ranking # # # # #
Equity (TTM) in Millions -14 -12 -12 6 8
Seq. Equity Change - - - -24.98 % -4.53 %
Seq. Net Income Change - - - - -

Back to ZVSA Management Effectiveness >> ZVSA's 5 Years Annual ROE >> Compare ZVSA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 



  News about Zyversa Therapeutics Inc Return on Equity ROE

ZyVersa Therapeutics Charts Path Forward Amidst Financial Challenges with Promising Obesity Treatment

In a recent letter to shareholders, Stephen C. Glover, CEO of ZyVersa Therapeutics, detailed the company’s ambitious plans for the next nine months centered around its investigational treatment, the Inflammasome ASC Inhibitor IC 100. Glover expressed optimism that this innovative therapy, aimed at mitigating chronic inflammation associated with obesity, could not only combat the disease effectively but also alleviate a range of related comorbidities, thereby offering a multifaceted solution to a growing health crisis.Obesity remains a pressing issue worldwide, affecting millions and leading to a myriad of health complications, including cardiovascular diseases, diabetes, and certain forms of cancer. The introduction of IC 100 seeks to address these complications at a cellular level by inhibiting the inflammasome ASC, which plays a critical role in the inflammatory processes associated with obesity. If successful in clinical trials, the drug could represent a significant advancement in obesity treatment, enhancing weight loss efforts while addressing the systemic inflammation that often accompanies this condition.

ZyVersa Therapeutics' Vision for 2024: Advancing the Boundaries of Renal and Inflammatory Disease Treatment

ZyVersa Therapeutics: Advancing Innovative Treatment for Renal and Inflammatory Diseases in 2024
WESTON, Fla., Jan. 03, 2024 - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; ZyVersa), a prominent clinical-stage specialty biopharmaceutical company has released a much-anticipated corporate outlook for 2024. In a recent Letter to Shareholders, Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President of ZyVersa, outlined the company s vision for the upcoming year and highlighted key milestones.
ZyVersa Therapeutics has rapidly emerged as a frontrunner in the field of drug development, aiming to revolutionize the treatment landscape for patients suffering from renal and inflammatory diseases with unmet medical needs. With a range of first-in-class drugs in development, ZyVersa is committed to improving the quality of life for millions across the globe.



ZVSA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2021)
2021
Total Equity in Millions -12 9 11 100 -2
Y / Y Equity Change - -23.1 % -88.89 % - -
Net Income in Millions -25 -9 -14 0 0
Y / Y Net Income Change - - - - -
Return On Equity - -110.53 % -126.85 % -0.24 % -

Back to ZVSA Management Effectiveness >> ZVSA's 5 Years Annual ROE >> Compare ZVSA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ZVSA's' Return on Equity at Yahoo Finance
ZVSA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ZVSA's Competitors
Subscribers only: Roe for Zyversa Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for ZVSA's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Xeris Biopharma Holdings Inc   791.74 %
Glucotrack Inc   581.98 %
Silexion Therapeutics Corp  516.87 %
Aveanna Healthcare Holdings Inc   242.29 %
Q32 Bio Inc   230.68 %
Emmis Acquisition Corp   224.85 %
Interpace Biosciences Inc   215.31 %
Coherus Oncology inc   214.57 %
Oncotelic Therapeutics Inc   183.27 %
Arbutus Biopharma Corp  169.38 %
Rigel Pharmaceuticals Inc  147.03 %
Fortress Biotech Inc   140.48 %
Halozyme Therapeutics Inc   126.27 %
Petros Pharmaceuticals inc   124.23 %
Advanced Biomed Inc.  121.71 %
Medpace Holdings Inc   120.89 %
Capforce Inc   110.42 %
Eli Lilly And Company  101.17 %
Qhslab Inc   91.63 %
Amgen Inc   89.41 %
Exelixis Inc   88.60 %
Entera Bio Ltd   87.97 %
Tg Therapeutics Inc   87.36 %
Alnylam Pharmaceuticals Inc   86.11 %
Zevra Therapeutics Inc   81.34 %
Pulmatrix Inc   78.57 %
Earth Science Tech Inc   71.44 %
Idexx Laboratories Inc  70.87 %
Elite Pharmaceuticals Inc   68.60 %
Escalon Medical Corp   66.85 %

Date modified: 2026-09-08T15:11:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.